Mechanisms of chronic allograft dysfunction

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 14-18

  Kamoun, Malek ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allograft dysfunction; Chronic rejection; Deterioration

Indexed keywords

ALLOANTIBODY; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TOLL LIKE RECEPTOR; IMMUNOLOGIC FACTOR;

ALLOIMMUNITY; B LYMPHOCYTE; DEMOGRAPHY; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SHORT SURVEY; ALLOTRANSPLANTATION; ANIMAL; GRAFT REJECTION; IMMUNOLOGY; REVIEW;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; ISOANTIBODIES; TOLL-LIKE RECEPTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745488184     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000194499.32398.32     Document Type: Short Survey

References (72)

1. Cornell L, Colvin R. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens. 2005;14:229-234.
2. Halloran PF. Call for revolution: a new approach to describing allograft deterioration. Am J Transplant. 2002;2:195-200.
3. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol. 1999;10:167-181.
4. Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant. 2005;5:1405-1414.
5. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
6. Meier-Kriesche H-U, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
7. Avihingsanon Y, Ma N, Pavlakis M, et al. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol. 2005;16:1542-1548.
8. Fishman JA. BK virus nephropathy: polyomavirus adding insult to injury. N Engl J Med. 2002;347:527-530.
9. Land W. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005;79:505-514.
10. Lattmann T, Hein M, Horber S, et al. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: Role of endothelin receptor signaling. Am J Transplant. 2005;5:1042-1049.
11. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-590.
12. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med. 2004;351:2761-2766.
13. Srinivas T, Kubilis P, Croker B. Macrophage index predicts short-term renal allograft function and graft survival. Transpl Int. 2004;17:195-201.
14. Palomar R, Ruiz J, Mayorga M, et al. The macrophage infiltration index and matrix metalloproteinase-II expression as a predictor of chronic allograft rejection. Transplant Proc. 2004;36:2662-2663.
15. Ozdemir BH, Ozdemir FN, Haberal N, et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. Am J Transplant. 2005;5:766-774.
16. Mas V, Alvarellos T, Giraudo C, et al. Intragraft messenger RNA expression of angiotensinogen: relationship with transforming growth factor beta-1 and chronic allograft nephropathy in kidney transplant patients. Transplantation. 2002;74:718-721.
17. Matl I, Viklickú O, Voska L, et al. The effect of different immunosuppressive regimens on TGF-1 expression in kidney transplant patients. Transpl Int. 2005;18:668-671.
18. Coupes B, Newstead C, Short C, et al. Transforming growth factor beta 1 in renal allograft recipients. Transplantation. 1994;57:1727-1731.
19. Jain S, Furness P, Nicholson M. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation. 2000;69:1759-1766.
20. Sharma V, Bologa R, Xu G, et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int. 1996;49:1297-1303.
21. Bottinger E, Letterio J, Roberts A. Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int. 1997;51:1355-1360.
22. Andrade CF, Waddell TK, Keshavjee S, et al. Innate immunity and organ transplantation: the potential role of Toll-like receptors. Am J Transplant. 2005;5:969-974.
23. Methe H, Zimmer E, Grimm C, et al. Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation. 2004;78:1324-1331.
24. Takemoto S, Port FK, Claas FHJ, et al. HLA matching for kidney transplantation. Hum Immunol. 2004;65:1489-1505.
25. Opelz G. Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation. 1997;64:1473-1475.
26. OPTN/SRTR. 2003 Annual Report [SRTR web site]. Tables 1.2, 1.3, 1.8, and fast facts about transplants for 2003. Available at: http://www.ustransplant. org. Accessed December 2, 2004.
27. Matas A, Gillingham K, Payne W, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation. 1994;27:857-859.
28. Ortiz F, Paavonen T, Tornroth T, et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol. 2005;16:817-824.
29. Sayegh M, Carpenter C. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 1996;13:221-229.
30. Vella J, Vos L, Carpenter C, et al. Role of indirect allorecognition in experimental late acute rejection. Transplantation. 1997;64:1823-1828.
31. Abe M, Kawai T, Futatsuyama K, et al. Postoperative production of antidonor antibody and chronic rejection in renal transplantation. Transplantation. 1997;63:1616-1619.
32. Baid S, Saidman S, Tolkoff-Rubin N, et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol. 2001;13:577-581.
33. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12:574-582.
34. McKenna R, Takamoto S, Terasaki P. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000;69:319-326.
35. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant. 2003;3:708-714.
36. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13:2371-2380.
37. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033-1041.
38. Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3:665-673.
39. Vongwiwatana A, Tasanarong A, Hidalgo LG, et al. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev. 2003;196:197-218.
40. Worthington J, Martin S, Al-Husseini D, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor or renal transplant outcome. Transplantation. 2003;75:1034-1040.
41. Sumitran S. Clinical importance of HLA-specific and non-HLA-specific antibodies in allogeneic kidney transplantation. Adv Nephrol Necker Hosp. 2000;30:29-39.
42. Katzlneson S, Bhaduri S, Cecka JM. Clinical aspects of sensitization. In: Cecka JM, Terasaki R, eds. Clinical Transplantation. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1997:285-296.
43. Sarwal M, Chua M, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003;349:125-138.
44. Constant S, Schweitzer N, West J, et al. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol. 1995;155:3734-3741.
45. Hayglass KT, Naides SJ, Scott CF Jr., et al. T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo. J Immunol. 1986;136:823-829.
46. Noorchashm H, Greeley S, Naji A. The role of T/B lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol Res. 2003;27:443-450.
47. Ron Y, Sprent J. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol. 1987;138:2848-2856.
48. Manz RA, Arce S, Cassese G, et al. Humoral immunity and long-lived plasma cells. Curr Opin Immunol. 2002;14:517-521.
49. Manz R, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388:133-134.
50. Slifka M, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol. 1998;10:252-258.
51. Slifka M, Antia R, Whitmire J, et al. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363-372.
52. Bernasconi N, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298:2199-2202.
53. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21:S35-S7.
54. Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med. 1984;160:1102-1113.
55. Hack N, Angra S, Friedman E, et al. Anti-idiotypic antibodies from highly sensitized patients stimulate B cells to produce anti-HLA antibodies. Transplantation. 2002;73:1853-1858.
56. Nelson JL. Microchimerism and scleroderma. Curr Rheumatol Rep. 1999;1:15-21.
57. SivaSai KS, Jendrisak M, Duffy BF, et al. Chimerism in peripheral blood of sensitized patients waiting for renal transplantation: clinical implications. Transplantation. 2000;69:538-544.
58. Davenport A, Younie ME, Parsons JE, et al. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant. 1994;9:1315-1319.
59. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation. 2001;71:1106-1112.
60. Pelletier RP, Hennessy PK, Adams PW, et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant. 2002;2:134-141.
61. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor or renal transplant outcome. Transplantation. 2003;75:1034-1040.
62. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69.
63. Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J. 2004;23:334-342.
64. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002;74:799-804.
65. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 1998;116:812-820.
66. Jaramillo A, Smith M, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation. 1999;67:1155-1161.
67. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation. 2002;74:268-277.
68. Dunn M, Crisp S, Rose M, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992;339:1566-1570.
69. Ferry BL, Welsh KI, Dunn MJ, et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol. 1997;5:17-24.
70. Fredrich R, Toyoda M, Czer L, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation. 1999;67:385-391.
71. Perrey C, Brenchley P, Johnson R, et al. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol. 1998;6:101-106.
72. Jin Y-P, Singh RP, Du Z-Y, et al. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol. 2002;168:5415-5423.